The content provided by this website is intended only for Australian healthcare professionals.
Please leave this site if you are not an Australian healthcare professional.
About Remsima®
Remsima® is a biosimilar monoclonal antibody developed by Celltrion. Comparability in safety, efficacy and quality between intravenous Remsima® and the originator biologic has been established.1
Remsima® is approved by the Therapeutic Goods Administration (TGA) as IV and SC formulations. Currently, Remsima® is available as a subcutaneous injection in a pre-filled pen and pre-filled syringe.1,2,3
Subcutaneous injection
Remsima® 120 mg solution for injection in pre-filled pen
Remsima® 120 mg solution for injection in
pre-filled syringe with needle guard
References
1. Remsima® Australian Product Information. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2020-PI-02540-1&d=202103141016933&d=20221121172310101. Last accessed: October 2023.
2. ARTG Search Result PF Pen. https://www.tga.gov.au/resources/artg/326188. Last Accessed: October 2023
3. ARTG Search Result PF Syringe. https://www.tga.gov.au/resources/artg/326187. Last Accessed: October 2023